AstraZeneca

TRANSCEND CLL 004 study data showed Breyanzi with Imbruvica achieved 86% response rate and 45% complete remission in relapsed/refractory CLL/SLL patients. Breyanzi, first CAR T therapy for CLL, targets unmet need in patients failing BTK and BCL2 inhibitors. Breyanzi sales projected to reach $2.6 billion by 2030.

HUTCHMED announces NMPA's Breakthrough Therapy Designation for ORPATHYS® and TAGRISSO® combo in EGFR mutation-positive NSCLC with MET amplification post-EGFR inhibitor therapy. The combination is being evaluated in China's Phase III SACHI trial, comparing its efficacy and safety to standard-of-care platinum-based doublet-chemotherapy.

Olaparib treatment improves long-term survival in women with high-risk, early-stage breast cancer and BRCA1/2 mutations, reducing cancer recurrence risk by 35% and death risk by 28%. After six years, 87.5% of treated patients were alive vs. 83.2% with placebo. The OlympiA trial underscores the importance of BRCA testing and the role of olaparib in targeting BRCA gene mutations.

HUTCHMED announces NMPA's Breakthrough Therapy Designation for ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) combo in EGFR mutation-positive NSCLC with MET amplification. The treatment is being evaluated in China's Phase III SACHI trial, comparing its efficacy and safety to standard platinum-based chemotherapy. NMPA grants BTD to therapies addressing life-threatening diseases with significant advantages over existing treatments, potentially expediting development and review.

The BMJ investigation reveals data reporting issues in the PLATO trial, which supported ticagrelor's approval. FDA initially rejected due to higher US deaths, but later approved. Subsequent studies failed to replicate PLATO's positive results, raising questions about its validity and ticagrelor's guidelines.

ICER's review found 5 of the 10 highest-priced U.S. drugs lacked new clinical evidence to justify price increases, costing payers $815M in 2023. ICER uses the GRADE approach to assess evidence quality, focusing on new, moderate- to high-quality evidence. Some drugs, like Keytruda, Imfinzi, and Opdivo, had price increases supported by new evidence from randomized control trials.

Hutchmed China announced NMPA granted breakthrough therapy designation to Orpathys and Tagrisso for EGFR mutation-positive NSCLC with MET amplification. The combination is being investigated in the phase three SACHI trial in China, comparing its efficacy and safety against standard platinum-based chemotherapy. BTD status aims to expedite development and review, potentially accelerating treatment availability for patients.

COVID-19 treatment companies focus on vaccines, antivirals, monoclonal antibodies, and supportive care. Vaccines like Pfizer-BioNTech and Moderna reduce severe cases, while antivirals like Remdesivir and Paxlovid limit viral replication. Monoclonal antibodies like Bamlanivimab offer early intervention. Supportive care remains crucial. Market growth is driven by COVID-19 spread, new variants, and increased demand for effective therapies. Government investments and rapid vaccine advancements accelerate treatment availability. The global pulmonary drug delivery systems market is projected to reach USD 97.8 billion by 2033.

The oral proteins and peptides market is projected to grow to $2.86 billion by 2028 at a CAGR of 22.4%, driven by factors like rising chronic diseases, biotechnology investments, and non-invasive treatments. Key advancements include novel oral peptides, AI in drug discovery, and oral insulin formulations.

HUTCHMED announced NMPA granted Breakthrough Therapy Designation to ORPATHYS (savolitinib) and TAGRISSO (osimertinib) for EGFR mutation-positive NSCLC with MET amplification. The combination is being evaluated in China's Phase III SACHI trial, comparing its efficacy and safety to standard platinum-based chemotherapy.